Literature DB >> 31509511

Prospective randomized comparison of repairing vesicovaginal fistula with or without the interposition flap: Result from a tertiary care Institute in Northern India.

Vishwajeet Singh1, Seema Mehrotra2, Ankur Bansal3, Asif Akhtar4, Rahul Janak Sinha1.   

Abstract

OBJECTIVE: Assessment of results of repairing vesicovaginal fistula (VVF) with or without the use of interposition flaps.
MATERIAL AND METHODS: This prospective randomized study was conducted between January 2012 to December 2017 in the Department of Urology, King George's Medical University, Lucknow, India. Obstetric and gynecological simple fistula of ≤4 cm were included for evaluation. Those with complex or complicated fistula or fistula due to malignancy were excluded. Patients were divided into two groups (group 1 and group 2) depending upon route of repair i.e., transvaginal or transabdominal, respectively, as per the characteristics and location of the fistula. These two groups of patients were randomized into two subgroups (1A, 1B and 2A, 2B) based on the inclusion or omission of the interposition flap during fistula repair. Perioperative and postoperative parameters (blood loss, mean operating time, hospital stay, and requirement of analgesics) and success rates of fistula repair were compared. All complications that occurred in the postoperative period till the last follow-up appointment were recorded. The Clavien-Dindo Classification was used to stratify the complications.
RESULTS: Fifty-seven patients underwent transvaginal repair in group 1 (29 with Martius flap: group 1A; 28 without Martius flap: group 1B), while 69 patients underwent transabdominal repair in group 2 (35 with interposition flap: group 2A; 34 without flap: group 2B). Blood loss, mean operating time, hospital stay, and the requirement of analgesics were comparable between each subgroup-1A versus 1B and 2A versus 2B, respectively. The overall success rate of repair across all groups was 96.04% (121/126). The success rate was 93.1% in transvaginal repair with Martius flap versus 96.43% in transvaginal repair with no flap (p=1.0). Success rate was 97.1% in transabdominal repair with an omental flap versus 97.06% in without an omental flap (p=1.0). Mean follow-up period was 39.6 months (range: 6-68 months). Out of 29 patients with Martius flap interposition, 9 (31.03%) of them reported a significantly reduced sensation on the labia majora. Of these 9 patients, 5 reported numbness while the remaining 4 experienced pain as compared to the patients in subgroup IB, who did not report any altered sensation in the labia. (p=0.0019).
CONCLUSION: The success rates are similar in simple VVF repair (fistula size less than 4 cm) irrespective of the use of interposition flaps. However, overall morbidities following repair with the interposition flap are higher when compared with repair without interposition flap, either by the transvaginal or by the transabdominal route.

Entities:  

Year:  2019        PMID: 31509511      PMCID: PMC6739083          DOI: 10.5152/tud.2019.85233

Source DB:  PubMed          Journal:  Turk J Urol        ISSN: 2149-3235


  15 in total

1.  Prevention of the development of a vesicovaginal fistula.

Authors:  E D Kursh; R M Morse; M I Resnick; L Persky
Journal:  Surg Gynecol Obstet       Date:  1988-05

2.  The Clavien-Dindo classification of surgical complications: five-year experience.

Authors:  Pierre A Clavien; Jeffrey Barkun; Michelle L de Oliveira; Jean Nicolas Vauthey; Daniel Dindo; Richard D Schulick; Eduardo de Santibañes; Juan Pekolj; Ksenija Slankamenac; Claudio Bassi; Rolf Graf; René Vonlanthen; Robert Padbury; John L Cameron; Masatoshi Makuuchi
Journal:  Ann Surg       Date:  2009-08       Impact factor: 12.969

3.  Repair of vesicovaginal fistula by the transabdominal route: outcome at a north Indian tertiary hospital.

Authors:  Vishwajeet Singh; Rahul Janak Sinha; Seema Mehrotra; S N Sankhwar; Sanjay Bhatt
Journal:  Int Urogynecol J       Date:  2011-09-02       Impact factor: 2.894

4.  Interposition flaps in transabdominal vesicovaginal fistula repairs: are they really necessary?

Authors:  D H Evans; S Madjar; V A Politano; D E Bejany; C M Lynne; A E Gousse
Journal:  Urology       Date:  2001-04       Impact factor: 2.649

5.  The use of modified Martius graft as an adjunctive technique in vesicovaginal and rectovaginal fistula repair.

Authors:  T E Elkins; J O DeLancey; E J McGuire
Journal:  Obstet Gynecol       Date:  1990-04       Impact factor: 7.661

6.  Is tissue interposition always necessary in transvaginal repair of benign, recurrent vesicovaginal fistulae?

Authors:  Thomas Pshak; Dmitriy Nikolavsky; Ryan Terlecki; Brian J Flynn
Journal:  Urology       Date:  2013-07-03       Impact factor: 2.649

7.  Role of the martius procedure in the management of urinary-vaginal fistulas.

Authors:  N P Rangnekar; N Imdad Ali; S A Kaul; H R Pathak
Journal:  J Am Coll Surg       Date:  2000-09       Impact factor: 6.113

8.  Transvaginal repair of complex and complicated vesicovaginal fistulae.

Authors:  Vishwajeet Singh; Rahul J Sinha; Satya N Sankhwar; Seema M Sinha; Priti Vatsal; Vaishali Jain
Journal:  Int J Gynaecol Obstet       Date:  2011-05-06       Impact factor: 3.561

9.  Lack of value of the Martius fibrofatty graft in obstetric fistula repair.

Authors:  A Browning
Journal:  Int J Gynaecol Obstet       Date:  2006-03-13       Impact factor: 3.561

10.  Management of vesicovaginal fistula: An experience of 52 cases with a rationalized algorithm for choosing the transvaginal or transabdominal approach.

Authors:  Rakesh Kapoor; M S Ansari; Pratipal Singh; Parag Gupta; Naval Khurana; Anil Mandhani; Deepak Dubey; Aneesh Srivastava; Anant Kumar
Journal:  Indian J Urol       Date:  2007-10
View more
  1 in total

1.  Radiation-Induced Recurrent Vesicovaginal Fistula-Treatment with Adjuvant Platelet-Rich Plasma Injection and Martius Flap Placement-Case Report and Review of Literature.

Authors:  Aleksandra Kołodyńska; Dominika Streit-Ciećkiewicz; Agata Kot; Iga Kuliniec; Konrad Futyma
Journal:  Int J Environ Res Public Health       Date:  2021-05-03       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.